<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041320</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">ARB II in chronic heart failure. Concidences and divergencies. Class effect?</dc:title>
<dc:description xml:lang="en">Although it is possible to suggest that the ACE inhibitor may have a certain class effect in regards to the benefits observed in the treatment of chronic heart failure, it does not seem reasonable that the same can be assumed in the case of ARB II. Morbidity-mortality studies in chronic heart failure have only been conducted with three of the seven ARB II presently commercialized in our country. These are losartan (ELITE II), valsartan (Val-HeFT) and candesartan (CHARM). The three studies have demonstrated the utility of these drugs, although with different nuances. In these clinical comments, we review the evidence available, stressing what effects could be common to all the ARB II, such as the prevention of diabetes or atrial fibrillation and what effects may only be attributable to some of these, at least up to now. However, new information of the already finished studies and some still on-going clinical trials may help us to know the effects of the ARB II in this disease more and betterAlthough it is possible to suggest that the ACE inhibitor may have a certain class effect in regards to the benefits observed in the treatment of chronic heart failure, it does not seem reasonable that the same can be assumed in the case of ARB II. Morbidity-mortality studies in chronic heart failure have only been conducted with three of the seven ARB II presently commercialized in our country. These are losartan (ELITE II), valsartan (Val-HeFT) and candesartan (CHARM). The three studies have demonstrated the utility of these drugs, although with different nuances. In these clinical comments, we review the evidence available, stressing what effects could be common to all the ARB II, such as the prevention of diabetes or atrial fibrillation and what effects may only be attributable to some of these, at least up to now. However, new information of the already finished studies and some still on-going clinical trials may help us to know the effects of the ARB II in this disease more and better</dc:description>
<dc:creator>Escobar Cervantes, C</dc:creator>
<dc:creator>Calderón Montero, A</dc:creator>
<dc:creator>Barrios Alonso, V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Si bien se puede sugerir que los inhibidores de la enzima de conversión de la angiotensina (IECA) quizás presentan un cierto efecto de clase en cuanto a los beneficios observados en el tratamiento de la insuficiencia cardíaca crónica, no parece razonable que se pueda asumir lo mismo en el caso de los antagonistas de los receptores de angiotensina II (ARA II). Sólo con tres de los 7 ARA II comercializados actualmente en nuestro país se han realizado hasta la fecha estudios de morbimortalidad en insuficiencia cardíaca crónica: losartán (ELITE II), valsartán (Val-HeFT) y candesartán (CHARM). Los tres estudios han demostrado la utilidad de estos fármacos, aunque con diferentes matices. En este comentario clínico revisamos las evidencias disponibles, resaltando qué efectos podrían ser comunes a todos los ARA II, como la prevención de diabetes o de fibrilación auricular y qué efectos pueden ser atribuidos solo a algunos de éstos, al menos hasta ahora. No obstante, nueva información de los estudios ya finalizados y algunos ensayos clínicos aún en marcha pueden ayudarnos a conocer más y mejor sobre los efectos de los ARA II en esta patología</dc:description>
<dc:source>Rev Clin Esp;205(10): 499-506, oct. 2005. tab</dc:source>
<dc:identifier>ibc-041320</dc:identifier>
<dc:title xml:lang="es">ARA II en insuficiencia cardíaca crónica. Coincidencias y divergencias. ¿Efecto de clase?</dc:title>
<dc:subject>^d1287^s22054</dc:subject>
<dc:subject>^d38265^s22006</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6486^s22057</dc:subject>
<dc:subject>^d3942^s22054</dc:subject>
<dc:subject>^d22832^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
